Noor Ul Ain Rehman
Fri, February 13, 2026 astatine 8:57 AM CST 2 min read
Pfizer Inc. (NYSE:PFE) further reported that the FDA acceptable a Prescription Drug User Fee Act enactment day successful Q2 2026. If approved, HYMPAVZI would supply a operation of bleed extortion with a straightforward, once-weekly subcutaneous injection medication that requires minimal mentation without a request for regular treatment-related laboratory monitoring for these difficult-to-treat diligent populations.
In different development, Citi reaffirmed its Hold standing connected Pfizer Inc. (NYSE:PFE) connected February 4, mounting a $26 terms target. The institution released its fiscal Q4 and full-year 2025 results connected February 3, announcing full-year revenues of $62.6 billion, reflecting a 2% year-over-year operational decline. It added that revenues grew 6% operationally erstwhile excluding contributions from Paxlovid and Comirnaty. Fiscal Q4 revenues came up to $17.6 billion, highlighting a 3% year-over-year operational decline.
Pfizer Inc. (NYSE:PFE) is simply a planetary biopharmaceutical institution that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures successful processing and emerging markets.
While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 day ago
4





English (CA) ·
English (US) ·
Spanish (MX) ·